News
BXPHF
0.020
NaN%
--
Botanix Updates Director Patricia Walker’s Equity Holdings After Option Expiry
TipRanks · 08/31 06:18
Botanix Pharmaceuticals Options Lapse, Streamlining Capital Structure
TipRanks · 08/31 06:17
Botanix Pharm: Strong Sofdra Adoption and Margin Upside Support Buy Rating with Unchanged $1 Price Target
TipRanks · 08/26 18:05
Botanix Revenue Surges on Sofdra Launch as Loss Narrows
TipRanks · 08/26 08:07
Botanix Issues 14 Million Unquoted Performance Rights Under Incentive Plan
TipRanks · 08/14 06:17
Botanix Pharmaceuticals Adds 2.3 Million Shares to ASX Quotation
TipRanks · 08/14 01:49
Botanix Pharmaceuticals Updates Market on Lapsing of 3.25 Million ASX Options
TipRanks · 08/03 04:37
Canaccord Genuity Sticks to Its Buy Rating for Botanix Pharmaceuticals Limited (BOT)
TipRanks · 07/30 00:35
Botanix: Sofdra Launch Momentum and Revenue Recovery Support Unchanged $1 Price Target and Buy Rating
TipRanks · 07/27 15:45
Botanix boosts Sofdra sales, tightens costs and fortifies IP as cash position strengthens
TipRanks · 07/26 23:48
Botanix Seeks ASX Quotation for 10.3 Million New Shares
TipRanks · 05/25 02:02
Botanix Securities Lapse Trims Potential Share Dilution
TipRanks · 05/21 15:05
Botanix Sets Stricter Securities Trading Rules to Bolster Market Confidence
TipRanks · 05/08 06:58
Botanix Shifts Registered Office to Melbourne as It Advances Hyperhidrosis Drug
TipRanks · 05/06 07:50
Canaccord Genuity Sticks to Their Buy Rating for Botanix Pharmaceuticals Limited (BOT)
TipRanks · 05/04 23:37
Botanix Taps Veteran Executive Paul Seaback as Chief Operating Officer
TipRanks · 05/03 23:26
H.C. Wainwright Sticks to Its Buy Rating for Botanix Pharmaceuticals Limited (BOT)
TipRanks · 04/29 11:29
Botanix issues investor update with detailed disclaimers and risk caveats
TipRanks · 04/29 00:02
Botanix builds Sofdra momentum, fortifies balance sheet and supply chain
TipRanks · 04/29 00:00
Botanix Director Granted Options Linked to Share Placement
TipRanks · 04/24 03:23
More
Webull provides a variety of real-time BXPHF stock news. You can receive the latest news about Botanix Pharma through multiple platforms. This information may help you make smarter investment decisions.
About BXPHF
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).